Rapid protein evolution by few-shot learning with a protein language model
Researchers introduce EVOLVEpro, a method merging PLMs and predictors to speed up protein evolution. It outperforms existing techniques, achieving significant property enhancements in just four rounds. The approach benefits various applications, showcasing AI's potential in protein engineering.
Read original articleResearchers have developed a new method called EVOLVEpro that combines protein language models (PLMs) and protein activity predictors to accelerate protein evolution. This few-shot active learning framework can enhance protein activity with just four rounds of evolution, outperforming current methods and achieving up to 100-fold improvement in desired properties. The study showcases EVOLVEpro's effectiveness in evolving proteins for various applications, including RNA production, CRISPR technology, genome editing, and antibody binding. The approach demonstrates the advantages of using small amounts of experimental data over zero-shot predictions, paving the way for AI-guided protein engineering in biology and medicine. The authors have disclosed competing interests and filed patents related to this work.
Related
Are AlphaFold's new results a miracle?
AlphaFold 3 by DeepMind excels in predicting molecule-protein binding, surpassing AutoDock Vina. Concerns about data redundancy, generalization, and molecular interaction understanding prompt scrutiny for drug discovery reliability.
ESM3, EsmGFP, and EvolutionaryScale
EvolutionaryScale introduces ESM3, a language model simulating 500 million years of evolution. ESM3 designs proteins with atomic precision, including esmGFP, a novel fluorescent protein, showcasing its potential for innovative protein engineering.
How AI Revolutionized Protein Science, but Didn't End It
Artificial intelligence, exemplified by AlphaFold2 and AlphaFold3, revolutionized protein science by accurately predicting protein structures. Despite advancements, AI complements rather than replaces biological experiments, highlighting the complexity of simulating protein dynamics.
AI Revolutionized Protein Science, but Didn't End It
Artificial intelligence, exemplified by AlphaFold2 and its successor AlphaFold3, revolutionized protein science by predicting structures accurately. AI complements but doesn't replace traditional methods, emphasizing collaboration for deeper insights.
Ex-Meta scientists debut gigantic AI protein design model
EvolutionaryScale introduces ESM3, a powerful AI protein design model trained on billions of sequences. Secured $142 million funding for drug development. Addresses concerns about AI-designed proteins. Researchers anticipate its impact.
Related
Are AlphaFold's new results a miracle?
AlphaFold 3 by DeepMind excels in predicting molecule-protein binding, surpassing AutoDock Vina. Concerns about data redundancy, generalization, and molecular interaction understanding prompt scrutiny for drug discovery reliability.
ESM3, EsmGFP, and EvolutionaryScale
EvolutionaryScale introduces ESM3, a language model simulating 500 million years of evolution. ESM3 designs proteins with atomic precision, including esmGFP, a novel fluorescent protein, showcasing its potential for innovative protein engineering.
How AI Revolutionized Protein Science, but Didn't End It
Artificial intelligence, exemplified by AlphaFold2 and AlphaFold3, revolutionized protein science by accurately predicting protein structures. Despite advancements, AI complements rather than replaces biological experiments, highlighting the complexity of simulating protein dynamics.
AI Revolutionized Protein Science, but Didn't End It
Artificial intelligence, exemplified by AlphaFold2 and its successor AlphaFold3, revolutionized protein science by predicting structures accurately. AI complements but doesn't replace traditional methods, emphasizing collaboration for deeper insights.
Ex-Meta scientists debut gigantic AI protein design model
EvolutionaryScale introduces ESM3, a powerful AI protein design model trained on billions of sequences. Secured $142 million funding for drug development. Addresses concerns about AI-designed proteins. Researchers anticipate its impact.